Celularity Inc
Celularity Inc. is a U.S.-based biotechnology company focused on developing and commercializing cell-based and biomaterial products derived from the placenta and other biological sources. The company’s platform combines regenerative medicine, immunology, and advanced biomaterials, with an emphasis on therapies and products that can be used in wound care, tissue repair, and potential cell therapy applications. Celularity has also relied on capital markets financing and equity-linked transactions to fund operations and development activities. Its business model is still in an early commercialization and development phase, so execution depends heavily on clinical, regulatory, and financing milestones.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment of placenta-derived and other cell-based therapeutic programs intended for tissue repair and immune-related applications.
Biologic materials and tissue-derived products used in wound healing and related clinical applications.
Preclinical, translational, and platform development work supporting future product candidates and partnerships.
Equity-linked and advisory arrangements that support liquidity and corporate development.
Products
Reported · share of revenue- Products49.6 %
- License Royalty and Other29.9 %
- Services20.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Celularity’s customers are primarily healthcare providers, clinicians, and institutions that use biologic wound care or regenerative products in patient treatment settings. In a broader sense, the company also serves pharmaceutical and biotech stakeholders through its development pipeline and platform capabilities. Because the company is still building commercial scale, some value creation comes from strategic investors, collaborators, and financing counterparties rather than only end-product buyers. Demand is tied to clinical adoption, reimbursement dynamics, and the ability to demonstrate safety and efficacy in regulated medical markets.
Hospitals, wound care centers, and clinics buy biologic products for patient treatment because they need clinically usable regenerative or wound-healing solutions.
Biotech, academic, and clinical partners engage with the platform to advance development programs and validate therapeutic applications.
Investors and financing counterparties provide funding through equity-linked instruments and private placements to support operations and development.
Patients and treating physicians are the eventual end market for approved cell therapy or regenerative medicine products.
Strategy
Celularity’s strategy appears centered on advancing its biologic platform while preserving liquidity through capital raises and equity-linked transactions. The company is using private placements, convertible notes, and registration rights structures to fund operations and support development milestones. It also appears to be maintaining flexibility through consulting and strategic advisory arrangements, which can help with business development and corporate execution. Over time, the strategic objective is likely to convert platform science into commercially viable wound care or therapeutic products that can attract clinical adoption and partnering interest.
The company needs external capital to fund ongoing development and corporate operations before product scale is achieved.
Clinical and commercial progress is necessary to convert the platform into durable revenue and strategic value.
Partnerships and advisory support can improve access to markets, capital, and commercialization pathways.
Geography
Celularity is headquartered in the United States and its reported financing and corporate activity are centered there. The available excerpts do not disclose a meaningful country-by-country revenue split, so the business profile should be viewed as U.S.-anchored with broader commercialization still developing. As a biotechnology company, its operating footprint is shaped more by clinical, regulatory, and capital-market access than by a large manufacturing or distribution network. Geographic exposure is therefore tied mainly to U.S. regulatory oversight, U.S. capital markets, and any future international commercialization or partnering.
Risks
Celularity faces the typical risks of an early-stage biotechnology company, including clinical failure, regulatory delays, and uncertain commercial adoption of its products. The company’s recent financing activity also highlights liquidity risk and dependence on external capital, which can be dilutive to shareholders. Convertible notes, preferred stock, and warrant structures can create share count expansion and pressure on the equity base if financing needs continue. More broadly, the company is exposed to reimbursement, manufacturing, quality control, and competitive risks common in regenerative medicine and wound care markets.
- Liquidity and financing dependenceImpact: HighLikelihood: High
The company has relied on private placements, convertible notes, and equity issuances to fund operations, indicating ongoing dependence on capital markets.
Exposure: Corporate funding and operating continuity
- Dilution from equity-linked securitiesImpact: HighLikelihood: High
Convertible notes and preferred stock can convert into common shares, increasing share count and reducing existing shareholders' ownership percentage.
Exposure: Shareholder dilution
- Clinical and regulatory executionImpact: High
Therapeutic and biologic programs require successful development, regulatory clearance, and evidence of safety and efficacy before meaningful commercialization.
Exposure: Pipeline and product approval
- Commercial adoption and reimbursementImpact: Medium
Even approved biologic products can face slow uptake if clinicians or payers do not support use or reimbursement is limited.
Exposure: Wound care and regenerative medicine markets
Accounting
Judgemental itemsThe company converted unsecured senior convertible notes into common stock, which affects dilution, equity classification, and non-cash financing accounting.
Impact: Can materially change share count and reported capital structure
The October 2025 private placement included Series A Preferred Stock and warrants, which may require fair value and conversion-feature analysis.
Impact: Can create non-cash gains/losses or balance sheet complexity
Common stock issued for consulting and advisory services must be measured and recognized as expense over the service period or at fair value.
Impact: Affects operating expenses and equity balances
Research, development, and business development costs are likely expensed as incurred, contributing to earnings volatility.
Impact: Impacts operating loss trends and comparability across quarters
Similar listed companies
Publicly listed companies with a comparable business focus.
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Celcuity Inc.
CELC · Services-Medical Laboratories
BioRestorative Therapies, Inc.
BRTX · Services-Misc Health & Allied Services, NEC
International Stem Cell CORP
ISCO · Pharmaceutical Preparations
Sanara MedTech Inc.
SMTI · Orthopedic, Prosthetic & Surgical Appliances & Supplies
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Last updated: 24/09/2026